Xi'an Sonwu Biotech Co., Ltd. is one of the most professional manufacturers and suppliers of raloxifene hydrochloride powder in China. We warmly welcome yuo to wholesale bulk raloxifene hydrochloride powder for sale here from our factory. Quality products and reasonable price are available.
Raloxifene Medication
Raloxifene hydrochloride powder is a selective estrogen receptor modulator. This drug interferes with some of the actions of estrogen and mimics other effects of estrogen. It effectively prevents menopausal osteoporosis, so it can replace estrogen to improve bone density. It is the hydrochloride salt form of raloxifene and has lipid-lowering, anti-osteoporosis activity. Raloxifene hydrochloride can specifically bind to estrogen receptors in the liver, bone, breast, and endometrium to promote or inhibit the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. The drug acts as an estrogen agonist in lipid metabolism, lowering total and LDL cholesterol levels. In tissues such as bone, it reduces bone resorption and bone turnover and increases bone mineral density. Acts as an estrogen antagonist in uterine and breast tissue. The drug also has antiproliferative effects in estrogen-sensitive breast disease.
Raloxifene hydrochloride is an investigational drug that currently acts as an estrogen to increase bone density. Because of this role, it is welcomed by the market. Xi'an Sonwu is a manufacturer with more than ten years of experience providing raw materials for production. If you are looking for raw raloxifene hydrochloride, you can contact Xi'an Sonwu.
Certificate Of Analysis
ITEMS | Limits/Specification | Results |
Purity (HPLC) | ≥99.0% | 99.53% |
Appearance | Light yellow powder | Complies |
Heavy metal | ≤10ppm | Complies |
Residue on ignition | ≤0.1% | 0.06% |
Loss on drying | ≤0.5% | 0.21% |
Chromatographic purity | Total: Not more than 2.0% Individual:Not more than 0.5% | 0.81% 0.24% |
Specific rotation | Between +19° and +24° | +22.5° |
Organic volatile impurties | Ethanol:not more than 0.5% | 0.35% |
Organic volatile impurties | Aether:not more than 0.5% | 0.19% |
Customers' Good Comment
Where To Buy Raloxifene HCL
Xi'an Sonwu Biotech Co., Ltd.'s business involves the healthcare industry worldwide, and has extensive experience in the healthcare industry. Xi'an Sonwu controls each product's color, shape, smell, etc., from many aspects to ensure the production of high-quality products. Xi'an Sonwu strives to strictly maintain every step, from the raw materials to the final presentation of products. Xi'an Sonwu seeks to serve every customer well and meet every customer's product quality and customization needs. So, if you need Raloxifene HCL, please find Xi'an Sonwu Biotech Co., Ltd.
Xi'an Sonwu makes sure of the product's quality and provides the sample. Here is the quantity.
Form | Sample Amount | MOQ |
Powder | 5g | 10g |
What Is The Drug Raloxifene Hydrochloride Used To Treat
As a SERM, raloxifene has selective agonistic or antagonistic activity on estrogenic tissues. It is an agonist on bone and lowers total cholesterol and LDE-cholesterol metabolism.
1. The effect on bones:
(1) After menopause, the available estrogen in the body decreases, which leads to a significant increase in bone resorption, and a considerable increase in the risk of bone loss and fracture. Bone loss is significantly accelerated in the first ten years after menopause. Although bone formation is also accelerated compensatory, it is not enough to compensate for the bone loss caused by enhanced bone resorption. Other possible risk factors for osteoporosis include early menopause, osteopenia, thin body, white and Asian race, and a family history of osteoporosis. Replacement therapy can often reverse excessive bone resorption. In postmenopausal women with osteoporosis, raloxifene can reduce the incidence of vertebral fractures, maintain bone mass and increase bone mineral density. Based on these risk factors, raloxifene is suitable for preventing osteoporosis in women within ten years of menopause whose vertebral BMD is between 1.0 and -2.5SD of the average value of ordinary young people, mainly considering that osteoporosis will occur in advanced age. Risk of osteoporotic fractures. Similarly, raloxifene for osteoporosis is suitable for those with osteoporosis or vertebral fractures whose spinal BMD is below the mean value of -2.5 SD for ordinary young people, regardless of their bone density.
(2) Raloxifene hydrochloride powder reduces bone resorption: the effect on bone is manifested as a decrease in serum and urine bone turnover markers. Radioactive calcium kinetic studies suggest that bone resorption decreases while BMD increases and the incidence of fractures decreases. A survey of raloxifene hydrochloride treatment showed that after 100 postmenopausal osteoporosis patients took raloxifene for six months, the femoral neck and bone mineral density of the lumbar spine increased significantly compared with before treatment, and bone turnover markers included serum ALP and bone density. Calcium decreased significantly compared with before treatment. There were no new fractures during the treatment and no apparent adverse drug reactions. The results of this study show that raloxifene hydrochloride can effectively correct a bone loss in postmenopausal women in the high turnover state, reduce the bone turnover rate, inhibit bone resorption, reduce the risk of fracture, and increase bone density. Good prevention and treatment drugs for postmenopausal osteoporosis are worthy of promotion and application.
2. Effects on lipid metabolism and cardiovascular risk factors: clinical studies have shown that 60 mg of raloxifene per day can significantly reduce total cholesterol by 3%-6% and LDL-cholesterol by 4%-10%. Fibrinogen decreased after three years of raloxifene treatment. In osteoporosis treatment studies, fewer patients required initiation of lipid-lowering compared with a placebo. Among patients enrolled in the Osteoporosis Treatment Study, raloxifene was not found to hurt the risk of cardiovascular events after four years of treatment.
What Is The Mechanism Of Action Of Raloxifene
Raloxifene works by binding to estrogen receptors. Raloxifene hydrochloride is a second-generation selective estrogen receptor modulator different from traditional or hormone replacement therapy drugs. After raloxifene hydrochloride binds to estrogen receptors, it can act as an estrogen agonist for bone turnover and some intermediate cardiovascular endpoints, such as serum lipids, lipoproteins, and fibrinogen. This binding results in the activation of estrogen agonism and blockade of estrogen antagonism in tissues expressing estrogen receptors. These receptors are described as two distinct subtypes, alpha estrogen receptors, and beta estrogen receptors. Thus, the expression of these receptors will alter the response of cells and tissues to estrogen.
In postmenopausal osteoporosis, bone turnover is dramatically increased. Bone resorption proceeds faster than bone formation, resulting in a progressive loss of bone mass and mineral density. This progressive loss represents an increased risk of fractures. Raloxifene inhibits short-term, and long-term accelerated bone resorption increases bone mineral density, and enhances bone strength. Other drugs used to treat osteoporosis are estrogens, bisphosphonates, selective estrogen receptor modulators, parathyroid hormone, and calcium and vitamin D. Long-term raloxifene can reduce the bone turnover rate, increase the bone mineral density of the vertebral body and femoral neck, and prevent vertebral bone fractures. Still, it has an estrogen-antagonistic effect on uterine or breast tissue. Antagonizing estrogen means not promoting endometrial hyperplasia and not increasing vaginal bleeding, thereby avoiding endometrial hyperplasia and other diseases caused by estrogen replacement therapy.
Side Effects Of Evista Raloxifene
Taboo
Contraindicated in pregnant women and those with current or previous venous thromboembolic disorders, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. Those who are allergic to the ingredients in raloxifene and those with decreased liver function and severe renal impairment are prohibited from taking it. Patients with unexplained uterine bleeding should also not take.
Precaution
Raloxifene may increase the risk of venous thromboembolic events, in which case the drug should be discontinued immediately or three days before immobilization. Wait until the above conditions are resolved, or the patient is fully mobile before initiating this product.
Medicine interactions
1. Simultaneous intake of calcium carbonate or antacids containing aluminum and magnesium hydroxide does not affect the systemic use of raloxifene.
2. Taking raloxifene and warfarin at one time does not change the pharmacokinetics of the two compounds. However, raloxifene can reduce the prothrombin time slightly. So prothrombin time must be monitored when raloxifene is combined with warfarin or other coumarin derivatives. In patients already receiving coumarin anticoagulants, the effect of raloxifene on prothrombin time may appear within a few weeks of treatment.
3. Raloxifene and cholestyramine should take in at different times. It can significantly reduce the absorption and enterohepatic circulation of raloxifene.
4. Concomitant administration with ampicillin will reduce the peak concentration of raloxifene.
5. Raloxifene can slightly increase the concentration of hormone-binding globulin, including sex hormone-binding globulin, thyroxine-binding globulin, and corticosteroid-binding globulin.
Drug overdose
In postmarketing spontaneous reports, overdose has been reported very rarely. The highest overdose was about 1.5 grams. No deaths related to overdose were reported. In adults, symptoms reported after single doses exceeding 120 mg include leg cramps and dizziness. In reports of an accidental overdose in children under two years of age, the maximum said dosage was 180 mg. Symptoms reported in children include ataxia, dizziness, vomiting, rash, and diarrhea.
Factory
1. Besides having its factory produce, manufacture, test, and store products, Xi'an Sonwu has a well-ordered, clean and tidy production department. Under the high standard requirements of Xi'an Sonwu, researchers can continuously develop high-quality new products.
2. Xi'an Sonwu has high requirements for the professionalism of its personnel, whether it is production, testing, or sales personnel. Strive to ensure every product is escorted from all aspects and provide strict data support and after-sales service.
Certificate
Packaging
Logistics
Xi'an Sonwu guarantees the products, but the most important thing is to help customers to receive the goods smoothly. Therefore, Xi'an Sonwu supplies all kinds of express delivery according to different needs.
FAQ
There may be differences in the usage and dosage of this product in different dosage forms and specifications. Please read the specific drug instructions or follow the doctor's advice.
1. The recommended dose is 60mg/day. You can take it without meal restrictions during the day.
2. The elderly do not need to adjust the dose.
3. Raloxifene requires long-term use due to the natural course of the disease.
4. Calcium and vitamin D are usually recommended for women with insufficient dietary calcium intake.
5. Or follow the doctor's advice.
If you are interested in raloxifene hydrochloride powder, contact Xi'an Sonwu. Find the email to get in touch with the best raloxifene hydrochloride price and high-quality manufacturer.
Email:sales@sonwu.com
Hot Tags: raloxifene hydrochloride powder, China, suppliers, manufacturers, factory, wholesale, buy, price, bulk, pure, raw, supply, for sale, Adenosine Monophosphate Powder, Emtricitabine API, Rapamycin powder, Atazanavir API, Lithium Orotate, 7 Hydroxy 4 methylcoumarin Powder
